A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Recurrent or Metastatic Solid Tumors Clinical Trial

Official title:
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Status Completed

Clinical Trial Summary

To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.

Clinical Trial Description

This is a Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity of MEDI6383 alone and in combination with MEDI4736 in adult subjects with recurrent or metastatic solid tumors. ;

Study Design

Related Conditions & MeSH terms

Recurrent or Metastatic Solid Tumors

Clinical Trial Details

NCT number	NCT02221960
Study type	Interventional
Source	MedImmune LLC
Contact
Status	Completed
Phase	Phase 1
Start date	September 15, 2014
Completion date	July 3, 2017

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06093698` - An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases	Phase 1
	Recruiting	`NCT06330064` - A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors	Phase 2